Molecular Biomarkers for Lung Adenocarcinoma: A Short Review

Author(s): Srikumar Chakravarthi*, Barani Karikalan

Journal Name: Current Cancer Therapy Reviews

Volume 17 , Issue 2 , 2021

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Lung cancer is a disease with higher death rates and is responsible for around 2 million deaths per year worldwide. Recently, several breakthroughs have been made in the field of lung cancer that has led to a revolution in the management of lung cancer patients. Identification of molecular markers and the implication of respective targeted therapies has been a great success in the treatment of lung adenocarcinoma patients. Despite the fact that targeted therapy of lung adenocarcinomas represents one of the significant milestones in the treatment of lung cancer that resulted in increased survival rates even in advanced stages, the mortality rates of lung cancer still remain to be significantly high. This warrants further research for gaining better insights into molecular alterations that can lead to newer innovations in targeted drug therapy towards lung adenocarcinoma. In this review, we briefly summarized the literature on molecular markers that are already in use. We also consolidated newer molecular markers that are under study with the potential for being targeted for therapies in future.

Keywords: Molecular markers, molecular/genetic alterations, genetic markers, target therapy, lung adenocarcinoma, nonsmall cell lung cancer.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Published on: 09 June, 2021
Page: [97 - 106]
Pages: 10
DOI: 10.2174/1573394716666200724164654
Price: $65

Article Metrics

PDF: 62